442 citations
- TU WienAT18 papers
- Medical University of ViennaAT13 papers
- International Institute for Applied Systems AnalysisAT5 papers
- Santa Fe InstituteUS4 papers
- Novartis (Switzerland)CH3 papers
- Tris Pharma (United States)US3 papers
- University of ViennaAT3 papers
- Yale UniversityUS3 papers
- Complexity Science HubAT2 papers
- TU Dortmund UniversityDE2 papers
- University Hospital MagdeburgDE2 papers
- University of Novi SadRS2 papers
4 papers · 1 filter
The use of external controls: To what extent can it currently be recommended?
Hans Ulrich Burger, Christoph Gerlinger, Chris Harbron +4
With more and better clinical data being captured outside of clinical studies and greater data sharing of clinical studies, external controls may become a more attractive alternati…
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials
Elias Laurin Meyer, Peter Mesenbrink, Cornelia Dunger-Baldauf +3
Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questio…
Analyzing genome-wide association studies with an FDR controlling modification of the Bayesian information criterion
Erich Dolejsi, Bernhard Bodenstorfer, Florian Frommlet
The prevailing method of analyzing GWAS data is still to test each marker individually, although from a statistical point of view it is quite obvious that in case of complex traits…
Quantifying age- and gender-related diabetes comorbidity risks using nation-wide big claims data
Peter Klimek, Alexandra Kautzky-Willer, Anna Chmiel +2
Currently emerging "big data" techniques are reshaping medical science into a data science. Medical claims data allow assessing an entire nation's health state in a quantitative wa…